Lv71
5000 积分 2022-08-05 加入
Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis
8天前
已完结
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
11天前
已完结
Effects of the Non-Steroidal MRA Finerenone with and without Concomitant SGLT2 Inhibitor Use in Heart Failure
20天前
已完结
Relationship Between Control of Cardiovascular Risk Factors and Chronic Kidney Disease Progression, Cardiovascular Disease Events, and Mortality in Chinese Adults
25天前
已完结
Comparative efficacy of sodium‐glucose co‐transporter‐2 inhibitors, glucagon‐like peptide‐1 receptor agonists and non‐steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta‐analysis
29天前
已完结
Excess Apolipoprotein B and Cardiovascular Risk in Women and Men
1个月前
已完结
Mineralocorticoid receptor antagonists with sodium–glucose co-transporter-2 inhibitors in heart failure: a meta-analysis
1个月前
已完结
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
1个月前
已完结
Statins aggravate insulin resistance through reduced blood glucagon-like peptide-1 levels in a microbiota-dependent manner
2个月前
已完结
Finerenone: First Approval
2个月前
已完结
皖公网安备34019202002308
